American Well (NYSE:AMWL) Raised to Hold at Wall Street Zen

American Well (NYSE:AMWL) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other equities analysts also recently issued reports on the company. Stifel Nicolaus cut their price objective on American Well from $6.00 to $5.00 and set a “hold” rating for the company in a research report on Friday. Weiss Ratings restated a “sell (e+)” rating on shares of American Well in a report on Wednesday, January 21st. Wells Fargo & Company cut their price target on American Well from $12.00 to $9.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Finally, Morgan Stanley decreased their price objective on shares of American Well from $10.50 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday, December 18th. One investment analyst has rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $7.42.

American Well Stock Up 24.1%

Shares of AMWL stock opened at $5.38 on Friday. The company has a market capitalization of $87.99 million, a P/E ratio of -0.90 and a beta of 1.36. American Well has a 12-month low of $3.71 and a 12-month high of $12.95. The firm has a 50-day moving average price of $4.68 and a 200 day moving average price of $5.47.

American Well (NYSE:AMWL) last posted its quarterly earnings data on Thursday, February 12th. The company reported ($1.52) earnings per share for the quarter, topping the consensus estimate of ($1.59) by $0.07. American Well had a negative net margin of 38.38% and a negative return on equity of 34.07%. The company had revenue of $55.31 million during the quarter, compared to analyst estimates of $52.71 million. As a group, research analysts expect that American Well will post -9.34 earnings per share for the current year.

Insider Buying and Selling

In other American Well news, insider Dmitry Zamansky sold 6,243 shares of the business’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $4.85, for a total transaction of $30,278.55. Following the completion of the sale, the insider directly owned 191,468 shares of the company’s stock, valued at approximately $928,619.80. The trade was a 3.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold 14,633 shares of company stock valued at $67,972 in the last three months. 11.82% of the stock is owned by company insiders.

Institutional Investors Weigh In On American Well

Institutional investors have recently modified their holdings of the business. Goldman Sachs Group Inc. raised its stake in shares of American Well by 280.6% during the first quarter. Goldman Sachs Group Inc. now owns 64,760 shares of the company’s stock worth $510,000 after buying an additional 47,745 shares during the last quarter. Jane Street Group LLC grew its holdings in American Well by 232.9% during the 1st quarter. Jane Street Group LLC now owns 64,112 shares of the company’s stock worth $505,000 after acquiring an additional 44,852 shares during the period. Corton Capital Inc. raised its position in shares of American Well by 71.7% during the 2nd quarter. Corton Capital Inc. now owns 27,402 shares of the company’s stock valued at $244,000 after acquiring an additional 11,445 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of American Well during the 2nd quarter valued at $89,000. Finally, Senvest Management LLC lifted its stake in shares of American Well by 0.3% in the 2nd quarter. Senvest Management LLC now owns 1,312,852 shares of the company’s stock valued at $11,671,000 after purchasing an additional 4,497 shares during the period. Institutional investors and hedge funds own 56.05% of the company’s stock.

Key Headlines Impacting American Well

Here are the key news stories impacting American Well this week:

• Positive Sentiment: Q4 results beat consensus: AMWL reported ($1.52) EPS vs. consensus ($1.59) and revenue of $55.31M vs. $52.71M expected — a modest beat that suggests underlying demand. Read More.
• Neutral Sentiment: Earnings call and transcript available; analysts and media are parsing commentary for signs of margin improvement and CAC trends. Read More.
• Neutral Sentiment: Independent write-ups (Zacks, Benzinga) provide metric-by-metric comparisons to estimates and discuss where growth drivers and cost levers may lie. Read More.
• Negative Sentiment: Guidance materially below Street expectations: Q1 revenue guide of $48.0M–$53.0M vs. consensus ~$59.9M, and FY2026 revenue guide of $195M–$205M vs. consensus ~$243.5M — the guidance shortfall is the clearest near-term driver of downward pressure on the stock. Read More.
• Negative Sentiment: Analyst action: Stifel cut its price target to $5.00 and moved to a “hold” — about a 7% downside from the current ~$5.38 level — reinforcing cautious sentiment after the outlook miss. Read More.

American Well Company Profile

American Well, operating under the trade name Amwell, is a Boston-based digital health company that develops and delivers telehealth solutions to healthcare providers, payers, employers and patients. Through its cloud-based platform, the company enables secure virtual visits, remote patient monitoring and integrated care coordination across a range of medical disciplines, including primary care, behavioral health, chronic disease management and urgent care.

The company’s core offering, the Amwell Telehealth Platform, facilitates live video consultations, asynchronous messaging, e-prescribing and electronic health record integration.